AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
AZN.US
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
1877.HK
688180.SHG
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
Ping An Health pins recovery hopes on new leadership
The ailing healthcare platform brought in a whole new management team three years ago to drive a business turnaround but it is changing leaders again Key Takeaways: The Covid pandemic…
1833.HK
Fresh test for cancer-screening firm Genetron after Nasdaq exit
The onetime star of the U.S. stock market is being privatized with the help of new investors as it adapts to tough challenges in China’s cancer-testing industry Key Takeaways: Genetron…
GTH.US
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
ANL.US
MedBot seeks commercial edge with dual-use surgical robot
The company’s orthopedic robot is the first domestically developed device to be approved for both hip and knee surgeries Key Takeaways: Even with its latest product, MicroPort MedBot faces intensifying…
2252.HK
